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In the adult human, the majority of hemato-
poietic stem and progenitor cells (HSPCs) re-
side  in  specialized  environments  within  the 
bone marrow collectively referred to as the he-
matopoietic  stem  cell  niche. The  number  of 
HSPCs in the circulation can be markedly in-
creased in response to several stimuli, including 
hematopoietic  growth  factors,  myeloablative 
agents, and environmental stresses such as in-
fection.  Recently,  mobilized  stem  cells  have   
become the preferred cellular source for re-
constitution  of  the  bone  marrow  after  mye-
loablative therapy because of their potency, 
predictability, and safety. G-CSF, a hematopoi-
etic growth factor, is the most commonly used 
mobilizing agent clinically. However, there is 
considerable  variability  in  the  magnitude  of 
HSPCs mobilized by G-CSF, and in 10% of 
cases, insufficient cells are mobilized for stem 
cell transplantation (Anderlini et al., 2001).   
An understanding of the mechanisms by which 
G-CSF elicits mobilization of HSPCs is critical 
to the development of novel more effective 
mobilizing agents.
There  is  accumulating  evidence  that  dis-
ruption of CXCR4/CXCL12 signaling is a 
key step in G-CSF–induced HSPC mobiliza-
tion. CXCL12 (SDF-1) is a chemokine consti-
tutively expressed at very high levels in the bone 
marrow and is a potent chemoattractant for   
HSPCs. In mice lacking CXCL12 (Nagasawa   
et  al.,  1996)  or  its  major  receptor  CXCR4 
(Zou et al., 1998), there is a failure of the mi-
gration of HSPCs from the fetal liver to the 
bone  marrow.  Moreover,  CXCR4/  bone 
marrow chimeras exhibit constitutive mobili-
zation and fail to mobilize HSPCs in response 
to G-CSF (Ma et al., 1999; Christopher et al., 
2009).  G-CSF  treatment  is  associated  with   
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Granulocyte colony-stimulating factor (G-CSF), the prototypical mobilizing cytokine, induces 
hematopoietic stem and progenitor cell (HSPC) mobilization from the bone marrow in a cell-
nonautonomous fashion. This process is mediated, in part, through suppression of osteoblasts 
and disruption of CXCR4/CXCL12 signaling. The cellular targets of G-CSF that initiate the 
mobilization cascade have not been identified. We use mixed G-CSF receptor (G-CSFR)–
deficient bone marrow chimeras to show that G-CSF–induced mobilization of HSPCs corre-
lates poorly with the number of wild-type neutrophils. We generated transgenic mice in 
which expression of the G-CSFR is restricted to cells of the monocytic lineage. G-CSF–
induced HSPC mobilization, osteoblast suppression, and inhibition of CXCL12 expression in 
the bone marrow of these transgenic mice are intact, demonstrating that G-CSFR signals in 
monocytic cells are sufficient to induce HSPC mobilization. Moreover, G-CSF treatment of 
wild-type mice is associated with marked loss of monocytic cells in the bone marrow. Finally, 
we show that bone marrow macrophages produce factors that support the growth and/or 
survival of osteoblasts in vitro. Together, these data suggest a model in which G-CSFR 
signals in bone marrow monocytic cells inhibit the production of trophic factors required for 
osteoblast lineage cell maintenance, ultimately leading to HSPC mobilization.
©  2011  Christopher  et  al.  This  article  is  distributed  under  the  terms  of  an   
Attribution–Noncommercial–Share  Alike–No  Mirror  Sites  license  for  the  first 
six  months  after  the  publication  date  (see  http://www.rupress.org/terms).   
After six months it is available under a Creative Commons License (Attribution– 
Noncommercial–Share Alike 3.0 Unported license, as described at http://creative-
commons.org/licenses/by-nc-sa/3.0/).
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thus, a role for reduced monocytes in this phenotype is possi-
ble. In this study, we used a genetic approach to systematically 
examine the contribution of neutrophils and other hemato-
poietic cell populations to G-CSF–induced HSPC mobiliza-
tion. We show that G-CSFR expression on monocytic cells in 
the bone marrow is sufficient to initiate HSPC mobilization 
by G-CSF.
RESULTS
The mobilization response to G-CSF correlates poorly  
with the number of wild-type neutrophils  
in the bone marrow
To evaluate the importance of neutrophils to G-CSF-induced 
mobilization, we generated a series of bone marrow chimeras 
by transplanting wild-type and Csf3r/ bone marrow cells in 
different ratios into lethally irradiated wild-type mice. Donor 
chimerism was assessed in peripheral blood leukocytes 6 wk 
after transplantation. As reported previously (Richards et al., 
2003), the contribution of Csf3r/ cells to the B cell lineage 
was near that expected based on the input ratio (Fig. S1). 
However, because of the marked competitive advantage of 
Csf3r+/+ cells to the neutrophil lineage, virtually all of the 
neutrophils in the circulation and bone marrow were derived 
from Csf3r+/+ cells (Fig. 1, D and E; and not depicted). More-
over, the number of neutrophils in the blood was similar in   
all of the chimeras (Fig. S2).
We next assessed the mobilization response to G-CSF in 
these chimeras by quantifying CFUs (CFU-C) in the periph-
eral blood, bone marrow, and spleen. We predicted that an in-
verse correlation between Csf3r/ donor input and HSPC 
mobilization  would  be  observed.  Indeed,  the  number  of 
CFU-Cs in blood and spleen after treatment with G-CSF was 
highest in the 3-to-1 (wild-type-to-Csf3r/) chimeras and 
progressively decreased with increasing Csf3r/ donor input 
(Fig. 1, A–C). Analysis of donor chimerism in mature neu-
trophils (Gr-1hi SSChi) in the bone marrow after G-CSF re-
vealed that the great majority of neutrophils were derived 
decreased CXCL12 mRNA and protein expression in the 
bone marrow and decreased CXCR4 expression on HSPCs 
(Petit et al., 2002; Lévesque et al., 2003a; Semerad et al., 2005; 
Christopher et al., 2009). A potential mechanism for the   
decreased CXCL12 expression is provided by the observation 
that G-CSF treatment is associated with a marked suppression 
of osteoblasts (Semerad et al., 2005; Katayama et al., 2006; 
Christopher and Link, 2008; Christopher et al., 2009), which 
are an important source of CXCL12 in the bone marrow 
(Ponomaryov et al., 2000; Semerad et al., 2005; Jung et al., 
2006;  Christopher  et  al.,  2009). The  importance  of  the 
CXCL12–CXCR4 axis is illustrated by the success of the 
CXCR4 inhibitor plerixafor (AMD3100) to rapidly mobilize 
HSPCs in humans and mice (Liles et al., 2003; Broxmeyer   
et al., 2007).
Through  the  study  of  G-CSF  receptor  (G-CSFR; 
Csf3r)/ bone marrow chimeras, we previously showed that 
G-CSFR signaling in hematopoietic cells, but not stromal 
cells, is required for HSPC mobilization by G-CSF (Liu et al., 
2000). Within the hematopoietic compartment, the G-CSFR 
is expressed on neutrophils, monocytes/macrophages, HSPCs, 
and a subset of B lymphocytes and NK cells. The simplest 
model suggests that G-CSF directly acts upon HSPCs to in-
duce their mobilization. However, strongly arguing against 
this model, in mixed bone marrow chimeras containing wild-
type and Csf3r/ HSPCs, both types of cells were mobilized 
equally after G-CSF treatment (Liu et al., 2000).
There is some evidence implicating neutrophils in G-CSF– 
induced  HSPC  mobilization.  During  G-CSF  treatment, 
neutrophils release certain proteases into the bone marrow 
microenvironment  (Lévesque  et  al.,  2001,  2002,  2003a,b; 
Heissig et al., 2002; Petit et al., 2002; Christopherson et al., 
2003). Although controversial, these proteases, through cleav-
age of CXCL12 (Christopherson et al., 2003; Lévesque et al., 
2003a), c-kit (Lévesque et al., 2003b), and  VCAM-1 (Lévesque 
et al., 2001), may contribute to HSPC mobilization. A previ-
ous study reported that depletion of neutrophils using an   
antibody against Gr-1 (Ly6C/G) results in reduced HSPC 
mobilization by G-CSF (Pelus et al., 2004). However, Gr-1 is 
expressed on both neutrophils and a subset of monocytes; 
Figure 1.  Neutrophil number in the bone marrow cor-
relates poorly with G-CSF–induced HSPC mobilization. 
Wild-type and Csf3r/ bone marrow cells were mixed at the 
indicated ratios and transplanted into irradiated recipients.  
6 wk later, the mixed bone marrow chimeras were treated 
with G-CSF (250 µg/kg/d G-CSF for 7 d), and the number of 
CFU-C in the peripheral blood (A), spleen (B), or bone marrow   
(C) was measured. As a control, a cohort of mixed chimeras 
was analyzed without G-CSF treatment (UnRx). Because 
similar results were obtained with each type of chimera, the 
untreated data were pooled. The percentage of neutrophils 
in the bone marrow derived from wild-type cells (D) and the 
absolute number of wild-type neutrophils per femur (E) were 
determined after 7 d of G-CSF administration. (F) The num-
ber of CFU-C in the blood versus the number of wild-type 
neutrophils in bone marrow. The Pearson r2 value is shown. 
Data represent the mean ± SEM of six to nine mice and is 
pooled from two independent transplantation experiments.  
*, P < 0.05 compared with untreated chimeras; +, P < 0.05 
compared with 3:1 chimeras.JEM VOL. 208, February 14, 2011 
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from wild-type (Csf3r+/+) cells in all of the chimeras (Fig. 1 D). 
In fact, the correlation between the number of wild-type 
neutrophils in the bone marrow and CFU-C in the blood 
was poor (Fig. 1, E and F).
G-CSF–induced HSPC mobilization is normal  
in lymphocyte-deficient mice
The  contribution  of  B  and T  lymphocytes  to  G-CSF– 
induced  HSPC  mobilization  is  controversial.  Reca  et  al. 
(2007)  reported  that  G-CSF–induced  mobilization  is  im-
paired in Rag2/, SCID, and Jh mice. In contrast, Katayama 
et al. (2006) reported that Rag1/ mice and IL-7R/ mice 
exhibited a normal mobilization response to G-CSF. In this 
paper, we characterized HSPC mobilization by G-CSF in two 
lymphocyte-deficient mouse strains, Rag1/ and NOD/scid/
IL-2null mice. Rag1/ mice lack mature B and T cells, and 
NOD/scid/IL-2null mice lack all B, T, and NK cells. Consis-
tent with a previous paper (Katayama et al., 2006), HSPC 
mobilization  in  Rag1/  mice  was  comparable  to  that  in 
wild-type mice (Fig. 2 A). In NOD/scid/IL-2null mice, the 
baseline level of circulating HSPC was increased and marked 
mobilization in response to G-CSF was observed (Fig. 2 B). 
These data demonstrate that B, T, and NK cells are not re-
quired for G-CSF–induced mobilization.
Generation of transgenic mice with monocyte-restricted 
expression of the G-CSFR
To evaluate the role of monocytes in G-CSF–induced mobi-
lization, we generated transgenic mice in which the CD68 
(macrosialin)  promoter  drives  expression  of  the  G-CSFR 
(Fig. 3 A). A previous study established that regulatory ele-
ments of the CD68 gene are sufficient to direct transgene ex-
pression to the monocyte/macrophage lineage (Lang et al., 
2002). Two transgenic founder lines were identified that ex-
pressed the GFP in circulating monocytes (unpublished data). 
The transgenic founder mice were crossed with Csf3r/ 
mice to obtain CD68:mGCSFR;Csf3r/ mice, hereafter re-
ferred to as CD68:G-CSFR mice. Because the phenotype of 
CD68 transgenic mice derived from the two founder lines 
was similar, the data have been pooled. It is of note that the 
Figure 2.  G-CSF–induced HSPC mobili-
zation is normal in Rag1/ and NOD/scid/
IL-2null mice. Wild-type, Rag1/ (A), or 
NOD/scid/IL-2null mice (B) were treated with 
G-CSF (250 µg/kg/d for 5 d) or left untreated. 
The number of CFU-C in the blood, bone mar-
row, and spleen was measured after 5 d of  
G-CSF. Data represent the mean ± SEM of 
four to five mice per genotype per treatment 
group and is pooled from four independent 
experiments. *, P < 0.01; **, P < 0.001.
Figure 3.  G-CSFR expression is mainly restricted to monocytic 
cells in CD68:G-CSFR mice. (A) Schematic of the CD68:G-CSFR trans-
gene. IRES, internal ribosomal entry sequence. (B) Representative histo-
grams showing biotinylated G-CSF binding in the absence (solid line) or 
presence (dashed line) of a 100-fold molar excess of unlabeled G-CSF in 
the indicated blood leukocyte population. G-CSFR surface expression is 
proportional to the difference in median fluorescence intensity (MFI) 
between the two curves. (C) The mean MFI in the indicated blood leuko-
cyte population is shown. Data represent the mean ± SEM of four to five 
mice per genotype and is pooled from four independent experiments.
CD68:G-CSFR mice were generated 
from  B6CDF1  donor  oocytes  and   
then backcrossed four generations onto 
a C57BL/6 background. To minimize 
the influence of strain effects on phenotype, littermate con-
trols were used in all studies.254 Monocytes mediate G-CSF–induced HSPC mobilization | Christopher et al.
blood monocytes with levels similar to that seen in wild-type 
or Csf3r+/ mice. G-CSFR expression was barely detectable 
on neutrophils, and no expression was detected on B or   
T lymphocytes. Similar data were observed using bone mar-
row cells (unpublished data). These data suggest that hemato-
poietic expression of the G-CSFR in CD68:G-CSFR mice is 
mainly limited to monocytic cells.
CD68:G-CSFR mice are neutropenic
G-CSFR signals on granulocytic precursors are required for 
normal cell proliferation and differentiation (Liu et al., 1996). 
G-CSFR expression in CD68:G-CSFR mice is predicted 
to be restricted to cells of the monocyte lineage. To test this 
prediction, we measured surface expression of the G-CSFR 
on  blood  leukocytes  using  a  biotinylated  G-CSF  binding   
assay (Liu et al., 1996). Consistent with previous results, in 
wild-type and Csf3r+/ mice, expression of the G-CSFR was 
highest in neutrophils, detectable but lower in monocytes, 
and undetectable in B or T cells (Fig. 3, B and C; and not de-
picted). As expected, G-CSFR expression was not detected 
on any blood leukocytes in Csf3r/ mice. In CD68:G-CSFR 
mice, the highest expression of the G-CSFR was detected on 
Table I.  Peripheral blood counts
Parameter Csf3r+/ Csf3r/ CD68:G-CSFR Csf3r+/ versus Csf3r/ Csf3r+/ versus CD68:G-CSFR
Hemoglobin (g/dL) 13.80 ± 1.01 15.57 ± 1.06 18.00 ± 2.83 NS NS
Platelets (K/µL) 820 ± 147 701 ± 90 678 ± 188 NS NS
Leukocytes (K/µL) 8.76 ± 1.82 8.51 ± 4.10 9.82 ± 2.56 NS NS
Neutrophils (K/µL) 1.38 ± 0.62 0.16 ± 0.03 0.24 ± 0.05 P < 0.001 P < 0.001
Monocytes (K/µL) 0.24 ± 0.12 0.12 ± 0.08 0.25 ± 0.06 NS NS
B cells (K/µL) 2.75 ± 0.57 3.53 ± 1.52 4.92 ± 1.53 NS P < 0.05
T cells (K/µL) 1.95 ± 0.75 2.23 ± 0.82 1.78 ± 0.42 NS NS
Values represent mean ± SD for two to five mice per genotype and is pooled from three independent experiments. Comparisons in the two right columns were made using a 
one-way ANOVA with Bonferroni’s post test corrected for multiple comparisons
Figure 4.  G-CSF–induced HSPC mobilization is normal in CD68:G-CSFR mice. Mice of the indicated genotype were treated with G-CSF for 7 d or 
left untreated. The number of KLS (A) or CFU-C (B) in the blood, bone marrow, and spleen on day 7 is shown. The mRNA expression in the bone marrow 
on day 7 of osteocalcin (C) or CXCL12 (D) relative to -actin is shown. Data represent the mean ± SEM of three to five mice per genotype per treatment 
group and is pooled from three independent experiments. *, P < 0.01 compared with untreated mice of the same genotype; **, P < 0.05 compared with 
untreated mice of the same genotype; †, P < 0.05; ‡, P = 0.07 compared with G-CSF–treated Csf3r+/ mice.JEM VOL. 208, February 14, 2011 
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We have previously shown that G-CSF–induced HSPC 
mobilization is associated with osteoblast suppression and de-
creased CXCL12 expression in the bone marrow (Christopher 
et al., 2009). We assessed osteoblast suppression by measuring 
mRNA expression of osteocalcin, a specific marker of mature 
osteoblasts  (Semerad  et  al.,  2005). As  reported  previously 
(Semerad et al., 2005), G-CSF treatment resulted in a signifi-
cant decrease in osteocalcin and CXCL12 mRNA expression in 
the bone marrow of control (Csf3r+/) mice (Figs. 4, C and D).   
A similar decrease was observed in CD68:G-CSFR but not 
Csf3r/ mice after G-CSF administration. Together, these 
data suggest that G-CSFR expression in monocyte lineage 
cells is sufficient to induce HSPC mobilization and osteo-
blast suppression.
G-CSF treatment of wild-type mice is associated with a loss 
of monocytic cells in the bone marrow
To assess the effect of G-CSF on monocytic cells in the 
bone marrow, we took advantage of CX3CR1GFP/+ trans-
genic  mice  in  which  monocytic  cells  express  the  GFP 
(Geissmann et al., 2003). Based on Gr-1 expression, bone mar-
row monocytes/macrophages can be divided into two distinct 
subsets: Gr-1high GFP+ inflammatory monocytes/macrophages 
and Gr-1low GFP+ resident monocytes/macrophages (Fig. 5 A; 
Geissmann et al., 2003). CX3CR1GFP/+ mice were treated 
Thus, we predicted that the loss of G-CSFR expression   
on granulocytic cells in CD68:G-CSFR mice would result   
in neutropenia. Indeed, CD68:G-CSFR mice display basal 
neutropenia that is similar in magnitude to that seen in 
Csf3r/ mice (Table I). Interestingly, CD68:G-CSFR mice 
had a modest but significant increase in circulating B lym-
phocytes. A nonsignificant trend to increased B lymphocytes 
also was seen in the Csf3r/ mice (Liu et al., 1996). All other 
measured  hematopoietic  parameters  were  normal  in  the 
CD68:G-CSFR mice.
G-CSF–induced HSPC mobilization is normal  
in CD68:G-CSFR mice
We next evaluated the mobilization response of these mice   
to G-CSF. Specifically, we measured the number of c-kit+ 
lineageSca-1+ (KLS) cells and CFU-C in the blood, bone 
marrow, and spleen after 7 d of G-CSF. Consistent with pre-
vious results (Liu et al., 1996), in Csf3r+/ mice, G-CSF adminis-
tration  resulted  in  a  significant  increase  in  KLS  cells  and 
CFU-Cs in the blood and spleen (Fig. 4, A and B). As ex-
pected, no mobilization was observed in Csf3r/ mice.   
G-CSF treatment of CD68:G-CSFR mice induced HSPC 
mobilization that was at least as great as that observed in 
control mice. In fact, a significantly greater number of KLS 
cells were mobilized to the spleen in CD68:G-CSFR mice.
Figure 5.  G-CSF treatment leads to a loss of monocytic cells from the bone marrow. CX3CR1GFP/+ mice were treated with PBS or G-CSF for 5–7 d 
and the flush and bone fractions harvested as described in Materials and methods. (A) Representative dot plot showing the gating strategy used to iden-
tify inflammatory (Gr-1high GFP+) and resident monocytes/macrophages (Gr-1low GFP+). (B) The absolute number of inflammatory and resident monocytes/
macrophages in the flushed and bone fractions are shown. Data represent the mean ± SEM of four mice per cohort pooled from two independent experi-
ments. *, P < 0.05; **, P < 0.005; ***, P < 0.001. (C) The percentage of inflammatory and resident monocytes in the flush fraction of bone marrow was 
determined at the indicated time points. In these experiments, wild-type mice rather than CX3CR1GFP/+ mice were used, and CD115 was used to identify 
monocytic cells. Data represent mean ± SEM of two to six mice per cohort pooled from four independent experiments. **, P < 0.005 compared with un-
treated mice as determined by one-way ANOVA with Dunnett’s post-test to correct for multiple comparisons.256 Monocytes mediate G-CSF–induced HSPC mobilization | Christopher et al.
macrophages (Fig. 6 A). Moreover, secretion of osteocalcin 
and CXCL12 into the conditioned media was significantly 
increased in cultures containing macrophages (Fig. 6, B and C). 
It is of note that no alkaline phosphatase colonies or osteocal-
cin or CXCL12 protein secretion were detected in cultures   
of macrophages alone (unpublished data). These data are   
consistent with a paper by Chang et al. (2008) showing 
that macrophages induced osteoblast mineralization in vitro.   
To determine whether macrophages produce a soluble factor 
that stimulates osteoblast development, we repeated these ex-
periments, this time including transwell cultures in which the 
macrophages were separated from the stromal cells by a semi-
permeable membrane (Fig. 6 D). Mature osteoblast devel-
opment, as measured by osteocalcin protein secretion into 
conditioned media, was partially induced in the transwell cul-
tures. Collectively, these data suggest that bone marrow macro-
phages produce factors, at least some of which are secreted, 
that support the growth and/or survival of osteoblasts.
DISCUSSION
The contribution of neutrophils to HSPC mobilization by 
G-CSF is controversial. Neutrophils are a major source of 
proteases that have been implicated in HSPC mobilization, 
including  neutrophil  elastase,  cathepsin  G,  and  MMP-9 
(Kjeldsen et al., 1994; Borregaard and Cowland, 1997). How-
ever,  the  importance  of  these  proteases  is  controversial,  as 
mice lacking these proteases exhibit a normal mobilization 
response to G-CSF (Robinson et al., 2003; Levesque et al., 
2004; Pelus et al., 2004). There is strong evidence showing 
that HSPC mobilization by the chemokine IL-8 is dependent 
with G-CSF for 5 d and the number of inflammatory and 
resident monocytes/macrophages in the bone marrow deter-
mined by flow cytometry. A recent study suggested that colla-
genase treatment of murine long bones after flushing of bone 
marrow yields a cell population enriched for stromal cells and 
stromal macrophages (Crocker and Gordon, 1985; Morikawa 
et al., 2009). Thus, in addition to our standard bone marrow 
harvesting, we also analyzed cells in the bone fraction ob-
tained after collagenase treatment of flushed femurs. In each 
fraction, the number of inflammatory monocytes/macrophages 
was significantly reduced (Fig. 5 B). A smaller decrease in 
resident  monocytes/macrophages  in  the  flushed,  but  not 
bone, fractions was also observed. We next examined the ki-
netics of monocyte/macrophage loss during G-CSF–induced 
mobilization (Fig. 5 C). Because CX3CR1GFP/+ mice were in 
limited supply, we performed these experiments using wild-
type mice, using CD115 to identify monocytic cells. Impor-
tantly,  the  decrease  in  the  number  of  inflammatory  and 
resident monocytes/macrophages in the bone marrow was 
maximal by 3 d of G-CSF treatment, a time point at which 
osteoblast suppression first becomes evident (Christopher and 
Link, 2008).
Macrophages support the growth of osteoblasts in vitro
To further evaluate the role of monocytes/macrophages in 
osteoblast growth and survival, we cultured bone marrow 
stromal cells in the presence or absence of bone marrow   
macrophages. Stromal cells cultured in the presence of macro-
phages generated many more alkaline phosphatase-positive 
(osteoblast lineage) cells than those cultured in the absence of 
Figure 6.  Macrophages support the growth of mature osteoblasts in vitro. Unfractionated bone marrow cells from wild-type mice were cultured for 
10 d and then sorted by flow cytometry into stromal (CD45 Ter119) and macrophage (CD45+ CD115+) cell populations. Stromal cells were cultured for an 
additional 14 d in the absence (No Mø) or presence (Mø) of an equal number of macrophages. Ascorbic acid and calcium were included in all cultures to 
stimulate mature osteoblast development. (A) Representative photomicrographs of cultures on day 14 that were stained for alkaline phosphatase. (B) Osteo-
calcin protein concentration in conditioned media was measured by ELISA at the indicated time points. (C and D) CXCL12 protein (C) and Osteocalcin (D) con-
centrations in conditioned media were measured by ELISA on day 14 of culture. Where indicated, the macrophages were separated from the stromal cells 
 by a semipermeable membrane (transwell). Data represent the mean ± SEM of three independent experiments. *, P < 0.05; **, P < 0.005; ***, P < 0.001.JEM VOL. 208, February 14, 2011 
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In this study, we provide novel evidence that G-CSFR 
signaling in monocytic cells is sufficient to induce HSPC 
mobilization. We generated transgenic mice in which ex-
pression of the G-CSFR is mainly limited to cells of the 
monocyte lineage and showed that G-CSF–induced HSPC 
mobilization, osteoblast suppression, and decrease in CXCL12 
expression are similar to that control mice. In the bone   
marrow, there are at least four distinct monocytic cell pop-
ulations: inflammatory monocytes/macrophages, resident 
monocytes/macrophages, myeloid dendritic cells, and os-
teoclasts. Because the CD68 transgene used in our study is 
expected to direct G-CSFR expression in each of these cell 
populations, all of them are candidates to mediate HSPC 
mobilization. There is considerable (though conflicting) data 
on the role of osteoclasts in HSPC mobilization. Kollet et al. 
(2006) reported that activation of osteoclasts by injection of 
RANKL  (RANK  ligand)  was  associated  with  moderate 
HSPC mobilization, and inhibition of osteoclasts, either ge-
netically by knocking out PTP or by injecting mice with 
calcitonin, blunts the mobilization response to G-CSF. It is   
of note that osteoclasts produce the protease cathepsin K, 
which can cleave CXCL12 in vitro (Drake et al., 1996;   
Kollet et al., 2006). In contrast, other studies indicate that   
osteoclasts may actually inhibit mobilization, as mice that 
were  given  pamidronate,  an  osteoclast-inhibiting  bisphos-
phonate, exhibit increased mobilization in response to G-CSF 
(Takamatsu et al., 1998; Winkler et al., 2010). In contrast to 
osteoclasts (Takamatsu et al., 1998; Winkler et al., 2010), we 
show that inflammatory and resident monocytes/macrophages 
decrease after G-CSF treatment. It is of note that the timing 
of the decrease in these cell populations during G-CSF treat-
ment is similar to that reported for the decrease in osteoblasts 
(Christopher and Link, 2008) and precedes HSPC mobiliza-
tion. Definitive identification of the monocytic cell popula-
tion that mediates G-CSF–induced HSPC mobilization will 
require further study.
In summary, we provide evidence that monocytic cells in 
the bone marrow are sufficient to elicit HSPC mobilization 
and osteoblast suppression by G-CSF. These data suggest a 
model in which monocyte lineage cells in the bone marrow 
produce trophic factors required for the maintenance of   
osteoblasts. G-CSF–induced suppression of monocytic cells 
and/or signaling in these cells results in decreased production 
of the putative trophic factors, suppression of osteoblast line-
age cells (and CXCL12 expression), and ultimately HSPC mo-
bilization. The precise monocytic cell population and factors 
produced by these cells that regulate osteoblast lineage cells 
are areas of active investigation.
MATERIALS AND METHODS
Mice.  Sex-  and  age-matched  wild-type,  Csf3r/,  and  CX3CR1GFP/+  
mice on a C57BL/6 background were maintained under SPF conditions   
according to methods approved by the Washington University Animal   
Studies Committee (Saint Louis, MO). The Csf3r/ mice have been previously 
described (Liu et al., 1996). The CX3CR1GFP/+ mice were a gift from   
D.  Littman  (Skirball  Institute  of  Biomolecular  Medicine,  New York 
School of Medicine, New York, NY).
on neutrophils. Csf3r/ mice, which are profoundly neutro-
penic, fail to mobilize in response to IL-8 (Liu et al., 1997). 
Moreover, antibody-mediated depletion of neutrophils (using 
anti-CD11a or anti–Gr-1 antibodies) abrogated IL-8–induced 
HSPC mobilization (Pruijt et al., 1998, 2002). With respect to 
G-CSF, Pelus et al. (2004) reported that neutrophil depletion 
using anti–Gr-1 antibodies attenuated G-CSF–induced HSPC 
mobilization. However, Gr-1 is expressed on both neutrophils 
and a subset of monocytes; thus, a role for reduced monocytes 
in this phenotype is possible. In the current study, we demon-
strate, using G-CSFR–deficient bone marrow chimeras, that the 
mobilization response to G-CSF is poorly correlated with the 
number of wild-type neutrophils. Moreover, CD68:G-CSFR 
mice, which are neutropenic and have barely detectable expres-
sion of G-CSFR on neutrophils, exhibit a normal mobilization 
response to G-CSF. These data, although not excluding a role   
for neutrophils, strongly suggest that G-CSF signals in neutro-
phils are not sufficient to induce normal HSPC mobilization.
The  contribution  of  lymphocytes  to  G-CSF–induced 
HSPC mobilization is also controversial. Reca et al. (2007) 
reported that G-CSF–induced mobilization is impaired in 
Rag2/, SCID, and Jh mice and that this deficit can be   
reversed through administration of complement-inducing   
immunoglobulin. In contrast, Katayama et al. (2006) reported 
that Rag1/ mice and IL-7R/ mice exhibited a normal 
mobilization response to G-CSF. Consistent with the latter 
findings, we observed that Rag1/ and NOD/scid/IL-2null 
mice exhibit a normal mobilization response to G-CSF. The 
basis for these discrepancies remains unclear. Although all of 
these mouse lines share deficits in B and T lymphopoiesis, 
there are subtle differences. For example, natural killer activ-
ity is normal in Rag1/ and Rag2/ mice but is absent in 
NOD/scid/IL-2null mice. In any case, our data strongly sug-
gest that neither B and T lymphocytes nor NK cells are re-
quired for a normal mobilization response to G-CSF.
There is accumulating evidence that monocyte lineage 
cells in the bone marrow contribute to osteoblast homeostasis 
and HSPC trafficking. Chang et al. (2008) demonstrated that 
macrophages are anatomically juxtaposed with endosteal   
osteoblasts, forming a canopy over the osteoblasts at sites of 
bone  formation.  Moreover,  they  showed  that  ablation  of 
monocytic cells using the MAFIA transgenic mouse model 
resulted in a loss of osteoblasts (Chang et al., 2008). Similarly, 
Winkler et al. (2010) recently showed that macrophage abla-
tion using the MAFIA transgenic mouse model or through 
administration of clodronate-loaded liposomes resulted in a 
loss of osteoblasts and HSPC mobilization. Finally, Chow et al. 
demonstrated in a companion paper in this issue that deple-
tion of monocytic lineage cells using a variety of methods is 
sufficient to induce mobilization of HSPCs. Together, these 
data strongly suggest that monocytic cells produce trophic 
factors required for osteoblast maintenance and HSPC reten-
tion. Consistent with this conclusion, we show that macro-
phages support osteoblast growth in vitro, at least in part, 
through production of a soluble factor. The identity of these 
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manufacturer’s instructions and resuspended in 150 µl RNase/DNase-free 
water. Real-time RT-PCR was performed using the TaqMan One-Step RT-
PCR Master Mix Reagents kit (Applied Biosystems) on a GeneAmp 5700 
Sequence Detection System (Applied Biosystems). The reaction mix consisted   
of 5 µl RNA, 12.5 µl RT-PCR mix, 200 nM of forward primer, 200 nM of re-
verse primer, 280 nM of internal probe, and 0.625 µl MultiScribe reverse tran-
scription and RNase inhibitor in a total reaction volume of 25 µl. Reactions 
were repeated in the absence of reverse transcription to confirm that DNA 
contamination was not present. RNA content was normalized to murine   
-actin. PCR conditions were 48°C for 30 min and 95°C for 10 min, fol-
lowed by 40 cycles of 95°C for 15 s and 60°C for 1 min. Primers were: 
CXCL12 forward, 5-GAGCCAACGTCAAGCATCTG-3; CXCL12 reverse, 
5-CGGGTCAATGCACACTTGTC-3;  CXCL12  dT-FAM/TAMRA 
probe,  5-TCCAAACTGTGCCCTTCAGATTGTTGC-3;  -actin  for-
ward,  5-ACCAACTGGGACGATATGGAGAAGA-3;  -actin  primer,   
5-TACGACCAGAGGCATACAGGGACAA-3; -actin dT-FAM/TAMRA 
probe, 5-AGCCATGTACGTAGCCATCCAGGCTG-3; osteocalcin for-
ward, 5-TCTCTCTGCTCACTCTGCTGGCC-3; osteocalcin reverse,   
5-TTTGTCAGACTCAGGGCCGC-3; and osteocalcin dT-FAM/TAMRA 
probe, 5-TGCGCTCTGTCTCTCTGACCTCACAGATGCCA-3.
Flow cytometry. Red blood cells in peripheral blood and bone marrow 
mononuclear cell preparations were lysed in Tris-buffered ammonium chlo-
ride buffer, pH 7.2, and incubated with the indicated antibody at 4°C for   
1 h in PBS containing 0.1% sodium azide, 1 mM EDTA, and 0.2% (wt/vol) 
BSA to block nonspecific binding. The following directly conjugated mono-
clonal antibodies were used: allophycocyanin–eFluor 780-conjugated rat anti–
mouse Gr-1 (RB6-8C5, IgG2b; eBioscience); allophycocyanin-conjugated 
rat anti–mouse CD115 (AFS98, IgG2a; eBioscience); FITC-conjugated rat 
anti–mouse  Gr-1  (RB6-8C5,  IgG2b;  eBioscience);  allophycocyanin- 
conjugated rat anti–mouse CD3e (17A2, IgG2b; eBioscience); and allophyco-
cyanin–eFluor 780-conjugated rat anti–mouse B220 (RA3-6B2, IgG2a; 
eBioscience). For KLS analysis, we used the following antibodies: PE-conjugated 
rat anti–mouse Gr-1 (RB6-8C5, IgG2b; eBioscience); PE-conjugated rat 
anti–mouse B220 (RA3-6B2, IgG2a; eBioscience); PE-conjugated Armenian 
hamster anti–mouse CD3e (145-2C11, IgG; eBioscience); PE-conjugated rat 
anti–mouse Ter-119  (TER-119,  IgG2b;  eBioscience);  rat  anti–mouse   
Sca-1 (D7, IgG2a; eBioscience); and rat anti–mouse c-kit (2B8, IgG2b;   
eBioscience). To assess surface G-CSFR expression, G-CSF was biotinylated 
using NHS-LC-biotin (Thermo Fisher Scientific) as previously described 
(Shimoda et al., 1992). Peripheral blood mononuclear cells were incubated at 
4°C for 1 h with biotinylated G-CSF (25 ng/106 cells) in the presence or ab-
sence of a 100-fold molar excess of nonlabeled G-CSF, followed by incuba-
tion with PE-conjugated streptavidin. All cells were analyzed on a FACScan 
flow cytometer.
In some cases, the bone fraction of the bone marrow was analyzed by 
flow cytometry. In brief, bone marrow was extracted from femurs either by 
flushing with PBS or by centrifugation at 3,300 g for 1 min at room tempera-
ture. The pellet was set aside for analysis as the flushed fraction. The flushed fe-
murs were then pulverized with a mortar and pestle, and the bone chips were 
incubated with PBS containing 2 mg/ml of type II collagenase (Worthington 
Biochemical) at 37°C for 60 min with agitation. After allowing the bone chips 
to settle by gravity, the cell suspension was harvested and analyzed.
CXCL12  and  osteocalcin  ELISAs.  For  ELISAs,  96-well  plates  were 
coated with 100 µl CXCL12 capture antibody (2 µg/ml) diluted in PBS and 
incubated overnight at room temperature. After incubation for 1 h at room 
temperature  with  300  µl  of  blocking  solution  (1%  BSA,  5%  sucrose,   
and 0.05% NaN3), a 100-µl sample was added to each well and incubated for 
2 h at room temperature. After washing, 100 µl polyclonal biotinylated   
anti–human CXCL12 (250 ng/ml) in ELISA diluent (0.1% BSA, 0.05% 
Tween 20 in Tris [tris(hydroxymethyl-)aminomethane)]–buffered saline,   
pH 7.3) was added to each well and incubated at room temperature for 2 h. 
The reaction was developed by successive incubations with 1 µg/ml horse-
radish peroxidase streptavidin, substrate solution, and 50 µl 2N H2SO4 to stop 
Generation of mixed chimeras. Wild-type (Ly5.1) or Csf3r/ (Ly5.2) 
bone marrow cells were harvested. A total of two million bone marrow cells 
were mixed at a 3:1, 1:1, 1:3, or 1:9 ratio and injected retroorbitally into le-
thally irradiated wild-type mice (Ly5.1). Recipient mice were conditioned 
with 1,000 cGy from a 137Cesium source at a rate of 95 cGy/min before 
transplantation. Prophylactic antibiotics (trimethoprim-sulfamethoxazole; 
Alpharma) were given during the initial 2 wk after transplantation. Mice 
were analyzed 8–10 wk after transplantation.
Generation of CD68:G-CSFR mouse. To express G-CSF receptor under 
the control of the CD68 promoter, we made use of a variant of the CD68 
promoter construct described by Lang et al. (2002), in which the 728 bp of 
sequence 5 to the ATG and the 83-bp first intron of the human CD68 gene 
were subcloned into the pUR19 backbone. A fragment containing bases 93–
2694 of the murine G-CSF receptor cDNA, which includes the entire cod-
ing region of the murine G-CSF receptor, was subcloned into this backbone 
3 of the first CD68 intron. An IRES-GFP cassette (derived from pIRES2-
eGFP; Takara Bio Inc.) was subcloned into the backbone 3 of the G-CSF 
receptor fragment. For injection into male nuclei of B6CDF1 zygotes, the 
construct was digested with DraI and purified according to standard proce-
dures. Offspring derived from the injection were screened by PCR for GFP. 
A sample of peripheral blood was taken from those mice positive for GFP by 
PCR and analyzed for the presence of GFP+ neutrophils and monocytes. 
Transgene-bearing  founder  mice  were  mated  with  C57BL/6  mice  with 
germline deletion of G-CSF receptor (Csf3r/). Two founder lines pro-
duced viable offspring. Initial characterization of these mice revealed similar 
mobilization responses to G-CSF, so the data from the two founder lines 
were pooled and are collectively referred to as CD68:G-CSFR mice.
Macrophage/osteoblast co-culture. Bone marrow cells were recovered 
from the femurs of wild-type mice by flushing with PBS. The femurs were 
then infused with PBS containing 50 mg/ml of type II collagenase (Worthing-
ton Biochemical) and incubated at 37°C for 30 min. The collagenase-treated 
femurs were flushed again with PBS. The cells were pooled (containing both 
hematopoietic and stromal cells) and cultured for 7 d in base media (-MEM 
with 10% fetal calf serum). On day 7 of culture, cells were trypsinized and 
stained with PE-conjugated anti–mouse CD115 and FITC-conjugated anti–
mouse CD45. CD45+ CD115+ (macrophages) and CD45 (stromal cells) 
were sorted separately using a MoFlo high-speed cell sorter (Dako). CD45 
cells were plated at 10,000 cells per well in a 24-well plate in the absence or 
presence of 20,000 CD115+ CD45+ cells. As a control, 20,000 CD115+ 
CD45+ were plated alone. In each case, after incubation for 1–2 d in base 
media, cells were cultured for an additional 14 d in base media supplemented 
with 10 mM -glycerophosphate and 50 µg/ml ascorbic acid. Alkaline phos-
phatase staining was performed on day 14 of culture, per the manufacturer’s 
instructions (Vector Laboratories).
G-CSF mobilization protocol. Recombinant human G-CSF (Amgen) 
was diluted in phosphate-PBS with 0.1% low endotoxin BSA (Sigma- 
Aldrich) and administered at a dose of 250 µg/kg/d either by daily subcuta-
neous injection for 5 d or by continuous infusion via subcutaneous osmotic 
pump for 7 d. Mice were analyzed 3–4 h after the final cytokine dose.
CFU-C assays. Blood, bone marrow, and spleen cells were harvested from mice 
using standard techniques, and the number of nucleated cells in these tissues was 
quantified using a Hemavet (Drew Scientific) automated cell counter. We plated 
10 µl of blood, 5 × 104 nucleated spleen cells, or 2.0 × 104 nucleated bone mar-
row cells in 2.5 ml methylcellulose media supplemented with a cocktail of   
recombinant cytokines (MethoCult 3434; STEMCELL Technologies Inc.).   
Cultures were plated in duplicate and placed in a humidified chamber with 5% 
CO2 at 37°C. After 7 d of culture, the number of colonies per dish was counted. 
The frequency of colonies per femur or spleen was determined based on the 
number of cells present in the cell suspension immediately after harvest.
Real-time quantitative RT-PCR. Femurs were flushed with a total of   
0.75 ml TRIzol reagent (Invitrogen). RNA was isolated according to the JEM VOL. 208, February 14, 2011 
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